Europe (WHO region) vs Mauritius: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Mauritius
100.0%
in 2022
Europe (WHO region) rank
2nd
Mauritius rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Mauritius
How they compare
Mauritius currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Mauritius's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 2 times across 18 shared years of data; in 2005 it was Mauritius ahead.
Europe (WHO region) ranks 2nd and Mauritius ranks 1st of 11 groups.
Mauritius has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Mauritius | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 20.2% | 92.0% | 71.8% | Mauritius |
| 2010s | 57.7% | 96.0% | 38.3% | Mauritius |
| 2020s | 94.3% | 100.0% | 5.7% | Mauritius |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Mauritius?
- Mauritius, at 100.0% against 90.0% in Europe (WHO region) as of 2022.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Mauritius?
- 10.0%, with Mauritius ahead.
- How many years of comparable data are there for Europe (WHO region) and Mauritius?
- 18 years are reported by both, from 2005 to 2022.
- How do Europe (WHO region) and Mauritius rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Mauritius ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.